NCT05258773View on ClinicalTrials.gov

Evaluation of the Presence of SENS-401 in the Perilymph

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

December 18, 2023

Study Completion Date

May 31, 2024

Conditions
Hearing Loss
Interventions
DRUG

SENS-401 (R-Azasetron Besylate)

Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.

Trial Locations (7)

Unknown

Royal Victorian Eye and Ear Hospital, Melbourne

Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux

Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied, Clermont-Ferrand

Centre Hospitalier Universitaire de Lille Hôpital Roger Salengro, Lille

Hôpital Edouard Herriot, Lyon

Groupe Hospitalier La Pitié-Salpétrière, Paris

Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Toulouse

Sponsors

Lead Sponsor

Sensorion
All Listed Sponsors
lead

Sensorion

INDUSTRY

NCT05258773 - Evaluation of the Presence of SENS-401 in the Perilymph | Biotech Hunter | Biotech Hunter